Bloomberg Businessweek

THE NEW RED SCARE

The National Institutes of Health and the FBI are purging Chinese scientists from U.S. research institutions. Civil liberties issues aside, this is no way to cure cancer

The dossier on cancer researcher Xifeng Wu was thick with intrigue, if hardly the stuff of a spy thriller. It contained findings that she’d improperly shared confidential information and accepted a half-dozen advisory roles at medical institutions in China. She might have weathered those allegations, but for a larger aspersion that was far more problematic: She was branded an oncological double agent.

In recent decades, cancer research has become increasingly globalized, with scientists around the world pooling data and ideas to jointly study a disease that kills almost 10 million people a year. International collaborations are an intrinsic part of the U.S. National Cancer Institute’s Moonshot program, the government’s $1 billion blitz to double the pace of treatment discoveries by 2022. One of the program’s tag lines: “Cancer knows no borders.”

Except, it turns out, the borders around China. In January, Wu, an award-winning epidemiologist and naturalized American citizen, quietly stepped down as director of the Center for Public Health and Translational Genomics at the University of Texas MD Anderson Cancer Center after a three-month investigation into her professional ties in China. Her resignation, and the departures in recent months of three other top Chinese American scientists from Houston-based MD Anderson, stem from a Trump administration drive to counter Chinese influence at U.S. research institutions. The aim is to stanch China’s well-documented, costly theft of U.S. innovation and know-how. The collateral effect, however, is to stymie basic science, the foundational research that underlies new medical treatments. Everything is commodified in the economic cold war with China, including the struggle to find a cure for cancer.

Behind the investigation that led to Wu’s exit—and other such probes across the country—is the National Institutes of Health, in coordination with the FBI. “Even something that is in the fundamental research space, that’s absolutely not classified, has an intrinsic value,” says Lawrence Tabak, principal deputy director of the NIH, explaining his approach. “This pre-patented material is the antecedent to creating intellectual property. In essence, what you’re doing is stealing other people’s ideas.”

The NIH, the world’s biggest public funder of basic biomedical research, wields immense power over the nation’s health-research community. It allocates about $26 billion a year in federal grants; roughly $6 billion of that goes to cancer research. At a June 5 hearing, NIH officials told the U.S. Senate Committee on Finance that the agency has contacted 61 research institutions about suspected diversion of proprietary information by grant recipients and referred 16 cases, mainly involving undisclosed ties to foreign governments, for possible legal

You're reading a preview, sign up to read more.

More from Bloomberg Businessweek

Bloomberg Businessweek8 min read
Now, About That Yield Curve
The chance of a recession in 2020 has Democratic campaign strategists feverish with anticipation—while trying not to show it—and President Trump even more amped up than usual. While Trump says he’s confident of the strength of the U.S. economy, his a
Bloomberg Businessweek10 min readFood & Wine
Impossible Foods And Beyond Meat Can’t Make Fake Burgers Fast Enough
Ethan Brown, chief executive officer of Beyond Meat Inc., doesn’t want to talk about his company’s stock price. He’s more than happy to talk about Beyond’s plant-derived meat matrix or its athlete spokespeople, or even how his products aren’t quite a
Bloomberg Businessweek3 min readPolitics
Can Germany Learn to Love Stimulus?
“Economic stimulus” is something of a dirty phrase in German policy circles. Since a splurge when the country reunified in 1990, the government has only once deliberately ramped up spending to revive growth. That was in the aftermath of the 2008 fina